Archive — US — turtlesai
Lunit Brings AI to ASCO 2025 with 12 Precision Oncology Studies
Lunit, a South Korean AI company, will present 12 studies at ASCO 2025 focusing on AI applications in precision oncology. Key findings include AI's ability to identify patients who could benefit from anti-HER2 therapies in biliary tract cancer and assess PD-L1 expression in lung cancer, demonstrating AI's potential to enhance treatment decisions in oncology.
Key points
- Lunit is presenting 12 studies at ASCO 2025 focused on AI in oncology.
- One study indicates AI can identify biliary tract cancer patients who may benefit from HER2-targeted therapies, showing strong agreement with pathologist-assessed scores.
- Another study reports 70% agreement between AI and expert pathologists for PD-L1 assessment in lung cancer and identifies additional candidates for immunotherapy.
- A third study predicts CLDN18.2 expression in gastric cancer using AI, achieving high AUROCs, suggesting effective pre-screening.
- Lunit's research underscores AI's increasing importance in precision medicine, with 9 additional abstracts covering topics like cancer druggability and tumor microenvironment.
Why it matters
- The increase in AI applications in healthcare aligns with the broader trend of integrating AI technologies in medicine for enhanced diagnostic accuracy.
- Similar advancements in precision oncology are seen across the industry, echoing the shift towards personalized treatment plans in 2025 and beyond.
- Lunit's progress contributes to the growing field of AI in cancer treatment, reflecting trends observed in major oncology conferences and publications.
Lunit's focus on AI for precision oncology at ASCO 2025 highlights significant advancements in cancer treatment methods, emphasizing the transformative role of technology in personalizing patient care.